Literature DB >> 16723560

Mechanism of enhanced activity of liposome-entrapped aminoglycosides against resistant strains of Pseudomonas aeruginosa.

Clement Mugabe1, Majed Halwani, Ali O Azghani, Robert M Lafrenie, Abdelwahab Omri.   

Abstract

Pseudomonas aeruginosa is inherently resistant to most conventional antibiotics. The mechanism of resistance of this bacterium is mainly associated with the low permeability of its outer membrane to these agents. We sought to assess the bactericidal efficacy of liposome-entrapped aminoglycosides against resistant clinical strains of P. aeruginosa and to define the mechanism of liposome-bacterium interactions. Aminoglycosides were incorporated into liposomes, and the bactericidal efficacies of both free and liposomal drugs were evaluated. To define the mechanism of liposome-bacterium interactions, transmission electron microscopy (TEM), flow cytometry, lipid mixing assay, and immunocytochemistry were employed. Encapsulation of aminoglycosides into liposomes significantly increased their antibacterial activity against the resistant strains used in this study (MICs of > or =32 versus < or =8 microg/ml). TEM observations showed that liposomes interact intimately with the outer membrane of P. aeruginosa, leading to the membrane deformation. The flow cytometry and lipid mixing assays confirmed liposome-bacterial membrane fusion, which increased as a function of incubation time. The maximum fusion rate was 54.3% +/- 1.5% for an antibiotic-sensitive strain of P. aeruginosa and 57.8% +/- 1.9% for a drug-resistant strain. The fusion between liposomes and P. aeruginosa significantly enhanced the antibiotics' penetration into the bacterial cells (3.2 +/- 2.3 versus 24.2 +/- 6.2 gold particles/bacterium, P < or = 0.001). Our data suggest that liposome-entrapped antibiotics could successfully resolve infections caused by antibiotic-resistant P. aeruginosa through an enhanced mechanism of drug entry into the bacterial cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16723560      PMCID: PMC1479138          DOI: 10.1128/AAC.01547-05

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  41 in total

1.  Trends and developments in liposome drug delivery systems.

Authors:  T Lian; R J Ho
Journal:  J Pharm Sci       Date:  2001-06       Impact factor: 3.534

2.  Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

Authors:  R M Shawar; D L MacLeod; R L Garber; J L Burns; J R Stapp; C R Clausen; S K Tanaka
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

3.  Demonstration of a fusion mechanism between a fluid bactericidal liposomal formulation and bacterial cells.

Authors:  S Sachetelli; H Khalil; T Chen; C Beaulac; S Sénéchal; J Lagacé
Journal:  Biochim Biophys Acta       Date:  2000-02-15

4.  Aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment.

Authors:  D L MacLeod; L E Nelson; R M Shawar; B B Lin; L G Lockwood; J E Dirk; G H Miller; J L Burns; R L Garber
Journal:  J Infect Dis       Date:  2000-03       Impact factor: 5.226

Review 5.  Liposome-based drug delivery systems.

Authors:  M Langner; T E Kral
Journal:  Pol J Pharmacol       Date:  1999 May-Jun

Review 6.  Multidrug efflux in Pseudomonas aeruginosa: components, mechanisms and clinical significance.

Authors:  K Poole; R Srikumar
Journal:  Curr Top Med Chem       Date:  2001-05       Impact factor: 3.295

Review 7.  Pathogen-host interactions in Pseudomonas aeruginosa pneumonia.

Authors:  Ruxana T Sadikot; Timothy S Blackwell; John W Christman; Alice S Prince
Journal:  Am J Respir Crit Care Med       Date:  2005-02-01       Impact factor: 21.405

Review 8.  Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis.

Authors:  David E Geller; William H Pitlick; Pasqua A Nardella; William G Tracewell; Bonnie W Ramsey
Journal:  Chest       Date:  2002-07       Impact factor: 9.410

9.  Enhanced activity of liposomal polymyxin B against Pseudomonas aeruginosa in a rat model of lung infection.

Authors:  Abdelwahab Omri; Zacharias E Suntres; Pang N Shek
Journal:  Biochem Pharmacol       Date:  2002-11-01       Impact factor: 5.858

10.  Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system.

Authors:  David E Geller; Margaret Rosenfeld; David A Waltz; Robert W Wilmott
Journal:  Chest       Date:  2003-01       Impact factor: 9.410

View more
  23 in total

Review 1.  Time for a change: addressing R&D and commercialization challenges for antibacterials.

Authors:  David J Payne; Linda Federici Miller; David Findlay; James Anderson; Lynn Marks
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-06-05       Impact factor: 6.237

Review 2.  Combatting antibiotic-resistant bacteria using nanomaterials.

Authors:  Akash Gupta; Shazia Mumtaz; Cheng-Hsuan Li; Irshad Hussain; Vincent M Rotello
Journal:  Chem Soc Rev       Date:  2019-01-21       Impact factor: 54.564

3.  Efficacy and safety of liposomal clarithromycin and its effect on Pseudomonas aeruginosa virulence factors.

Authors:  Mai Alhajlan; Moayad Alhariri; Abdelwahab Omri
Journal:  Antimicrob Agents Chemother       Date:  2013-04-01       Impact factor: 5.191

Review 4.  Nanoparticle-based local antimicrobial drug delivery.

Authors:  Weiwei Gao; Yijie Chen; Yue Zhang; Qiangzhe Zhang; Liangfang Zhang
Journal:  Adv Drug Deliv Rev       Date:  2017-09-20       Impact factor: 15.470

5.  Potentiality of Melittin-Loaded Niosomal Vesicles Against Vancomycin-Intermediate Staphylococcus aureus and Staphylococcal Skin Infection.

Authors:  Sirikwan Sangboonruang; Natthawat Semakul; Mohammad A Obeid; Marta Ruano; Kuntida Kitidee; Usanee Anukool; Kidsadagon Pringproa; Panuwan Chantawannakul; Valerie A Ferro; Yingmanee Tragoolpua; Khajornsak Tragoolpua
Journal:  Int J Nanomedicine       Date:  2021-11-16

6.  Liposomal nanoparticles control the uptake of ciprofloxacin across respiratory epithelia.

Authors:  Hui Xin Ong; Daniela Traini; David Cipolla; Igor Gonda; Mary Bebawy; Helen Agus; Paul M Young
Journal:  Pharm Res       Date:  2012-07-26       Impact factor: 4.200

7.  Vancomycin-eluting niosomes: a new approach to the inhibition of staphylococcal biofilm on abiotic surfaces.

Authors:  Heba S Barakat; Mervat A Kassem; Labiba K El-Khordagui; Nawal M Khalafallah
Journal:  AAPS PharmSciTech       Date:  2014-06-04       Impact factor: 3.246

8.  Effective Treatment of Mycobacterium avium subsp. hominissuis and Mycobacterium abscessus Species Infections in Macrophages, Biofilm, and Mice by Using Liposomal Ciprofloxacin.

Authors:  James D Blanchard; Valerie Elias; David Cipolla; Igor Gonda; Luiz E Bermudez
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

9.  Activity and interactions of liposomal antibiotics in presence of polyanions and sputum of patients with cystic fibrosis.

Authors:  Misagh Alipour; Zacharias E Suntres; Majed Halwani; Ali O Azghani; Abdelwahab Omri
Journal:  PLoS One       Date:  2009-05-28       Impact factor: 3.240

10.  Liposomal encapsulated rhodomyrtone: a novel antiacne drug.

Authors:  Julalak Chorachoo; Thanaporn Amnuaikit; Supayang P Voravuthikunchai
Journal:  Evid Based Complement Alternat Med       Date:  2013-05-16       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.